LATEST TWEETS - CURATED BY HASH FINANCE

Agios Pharmaceuticals Inc $AGIO Given Consensus Recommendation of “Hold” by Brokerages https://t.co/G2lDlpdMTf
Week Herald (WeekHerald) 12 hours ago
Agios Pharmaceuticals Inc $AGIO Receives $79.80 Average Price Target from Brokerages https://t.co/SxdSEDJ484
$27.49 Million in Sales Expected for Agios Pharmaceuticals Inc $AGIO This Quarter https://t.co/O2VUPk9NTw
Brokerages Expect Agios Pharmaceuticals Inc $AGIO to Announce -$1.90 EPS https://t.co/3sBu6KEZhL
Agios Pharmaceuticals $AGIO Upgraded to Hold at Zacks Investment Research https://t.co/yaVYBNiYFX
Agios Pharmaceuticals $AGIO Upgraded to Hold at Zacks Investment Research https://t.co/s22N75kYPb
Agios Pharmaceuticals $AGIO Stock Rating Upgraded by BidaskClub https://t.co/7TLclhaicS
Agios Pharmaceuticals $AGIO Lifted to “Hold” at BidaskClub https://t.co/R0UFe6VE4W
Agios Pharmaceuticals $AGIO Lifted to “Hold” at BidaskClub https://t.co/KEDpo32w9a
VOLUME RADAR ALERT: $AGIO Agios Pharmaceuticals, Inc 📈 TradeIdeas via https://t.co/VS8RO1bzXJ to FREE Trading Room
Agios Pharmaceuticals Inc $AGIO Expected to Announce Quarterly Sales of $27.49 Million https://t.co/t19AURjD09 #stocks
Agios Pharmaceuticals $AGIO Upgraded to “Hold” by BidaskClub https://t.co/ZIOm6oObqI
Agios Pharmaceuticals $AGIO Upgraded at BidaskClub https://t.co/qk0c1RQxDJ
Agios Pharmaceuticals $AGIO Upgraded to Hold by Zacks Investment Research https://t.co/rkzYXrfBiG
$AGIO Phase 1 A Safety and Pharmacokinetic Study of AG-881 in Healthy Male Participants Following Administration of… https://t.co/yUdMwCtkdc
-$1.90 EPS Expected for Agios Pharmaceuticals Inc $AGIO This Quarter https://t.co/sXyXE8QZO9
Agios Pharmaceuticals Inc $AGIO Expected to Post Earnings of -$1.90 Per Share https://t.co/gg9dMrPmEk #stocks
Agios Pharmaceuticals $AGIO Rating Increased to Hold at Zacks Investment Research https://t.co/N3AWNl5HTd
Agios Pharmaceuticals $AGIO Rating Increased to Hold at Zacks Investment Research https://t.co/szblI526FA
Agios Pharmaceuticals $AGIO Rating Increased to Hold at Zacks Investment Research https://t.co/Q0kOxgMNke